McGill IBD logo
Donate

MUHC Publications: November 2023 – November 2024

MUHC Activities

  1. Management of ulcerative colitis: where are we at and where are we heading? Abbas A, Di Fonzo DMP, Wetwittayakhlang P, Al-Jabri R, Lakatos PL, Bessissow T. Expert Rev Gastroenterol Hepatol. 2024 Oct 29. doi: 10.1080/17474124.2024.2422370. Online ahead of print.PMID: 39470444
  2. Advanced combination therapy: is it the best way to break the therapeutic ceiling? Wetwittayakhlang P, Lakatos PL.Therap Adv Gastroenterol. 2024 Oct 24;17:17562848241272995. doi: 10.1177/17562848241272995. eCollection 2024.PMID: 39474440 Free PMC article.
  3. Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Bacsur P, Resál T, Sarlós P, Iliás Á, Dalma Sümegi L, Kata D, Dávid A, Farkas B, Ivány E, Bálint A, Bősze Z, Fábián A, Bor R, Szepes Z, Afif W, Bessissow T, Farkas K, Lakatos PL, Molnár T.Therap Adv Gastroenterol. 2024 Oct 16;17:17562848241290636. doi: 10.1177/17562848241290636. eCollection 2024.PMID: 39464507 Free PMC article.
  4. Improving access to inflammatory bowel disease care in Canada: The patient experience. Lalani S, Mathias H, Heisler C, Rohatinsky N, Mirza RM, Kits O, Zelinsky S, Nguyen G, Lakatos PL, Fowler S, Rioux K, Jones JL.J Health Serv Res Policy. 2024 Sep 2:13558196241276979. doi: 10.1177/13558196241276979. Online ahead of print.PMID: 39222410
  5. The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease. Angyal MM, Janssen MF, Lakatos PL, Brodszky V, Rencz F.Eur J Health Econ. 2024 Aug 30. doi: 10.1007/s10198-024-01719-6. Online ahead of print.PMID: 39212881
  6. The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review. Shehab M, De Marco D, Lakatos PL, Bessissow T. Expert Opin Biol Ther. 2024 Aug;24(8):733-746. doi: 10.1080/14712598.2024.2383882. Epub 2024 Jul 24.PMID: 39045643 Review.
  7. Serrated Polyps in Inflammatory Bowel Disease Indicate a Similar Risk of Metachronous Colorectal Neoplasia as in the General Population. Medawar E, Djinbachian R, Crainic IP, Safih W, Battat R, Mccurdy J, Lakatos PL, von Renteln D.Dig Dis Sci. 2024 Jul;69(7):2595-2610. doi: 10.1007/s10620-024-08456-z. Epub 2024 May 3.PMID: 38700631
  8. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years. Barkai LJ, Gonczi L, Balogh F, Angyal D, Farkas K, Farkas B, Molnar T, Szamosi T, Schafer E, Golovics PA, Juhasz M, Patai A, Vincze A, Sarlos P, Farkas A, Dubravcsik Z, Toth TG, Szekely H, Miheller P, Lakatos PL, Ilias A.Sci Rep. 2024 Jun 28;14(1):14909. doi: 10.1038/s41598-024-65987-1.PMID: 38942890 Free PMC article.
  9. Efficacy of Vonoprazan vs. Intravenous Proton Pump Inhibitor in Prevention of Re-Bleeding of High-Risk Peptic Ulcers: A Randomized Controlled Pilot Study. Pattarapuntakul T, Wong T, Wetwittayakhlang P, Netinatsunton N, Keeratichananont S, Kaewdech A, Jandee S, Chamroonkul N, Sripongpun P, Lakatos PL.J Clin Med. 2024 Jun 20;13(12):3606. doi: 10.3390/jcm13123606.PMID: 38930134 Free PMC article.
  10. How close are we to a success stratification tool for improving biological therapy in ulcerative colitis? Wetwittayakhlang P, Kotrri G, Bessissow T,Lakatos PL.Expert Opin Biol Ther. 2024 Jun;24(6):433-441. doi: 10.1080/14712598.2024.2371049. Epub 2024 Jun 26.PMID: 38903049 Review.
  11. Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare Delivery. Herauf M, Coward S, Peña-Sánchez JN, Bernstein CN, Benchimol EI, Kaplan GG; Canadian Gastro-Intestinal Epidemiology Consortium (Lakatos PL). Gastroenterology. 2024 Jun;166(6):949-956. doi: 10.1053/j.gastro.2024.02.016. Epub 2024 Feb 18.PMID: 38378092 Free article.No abstract available.
  12. Unravelling the Smoke Trail: Maternal Smoking, Childhood Exposure, and their Impact on Inflammatory Bowel Diseases. Wetwittayakhlang P, Lakatos PL.J Crohns Colitis. 2024 May 31;18(5):659-660. doi: 10.1093/ecco-jcc/jjae032.PMID: 38498342 No abstract available.
  13. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, Farkas B, Katsanos K, Michalopoylos G, Ribaldone DG, Attauabi M, Zhao M, Barak HA, Yanai H, Bezzio C, Rispo A, Castiglione F, Bar-Gil Shitrit A, Pugliese D, Armuzzi A, Savarino EV, Kolar M, Lukáš M, Chashkova E, Filip R, Rozieres A, Nancey S, Krznarić Ž, Schäfer E, Szamosi T, Sarlós P, Franko M, Drobne D, Knyazev OV, Kagramanova AV, Limdi J, Wetwittayakhlang P, Lakatos PL, Maharshak N, Bannon L, Nyári T, Szepes Z, Farkas K; TFB Study Group; Molnár T.Inflamm Bowel Dis. 2024 May 2;30(5):768-779. doi: 10.1093/ibd/izad135.PMID: 37542737 Free PMC article.
  14. Burden of Mental Health among Patients with Inflammatory Bowel Disease-A Cross-Sectional Study from a Tertiary IBD Center in Hungary. Lontai L, Elek LP, Balogh F, Angyal D, Pajkossy P, Gonczi L, Lakatos PL, Iliás Á.J Clin Med. 2024 Mar 29;13(7):2002. doi: 10.3390/jcm13072002.PMID: 38610767 Free PMC article.
  15. Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system. Bacsur P, Wetwittayakhlang P, Resál T, Földi E, Vasas B, Farkas B, Rutka M, Bessissow T, Afif W, Bálint A, Fábián A, Bor R, Szepes Z, Farkas K, Lakatos PL, Molnár T.Therap Adv Gastroenterol. 2024 Mar 21;17:17562848241239606. doi: 10.1177/17562848241239606. eCollection 2024.PMID: 38524790 Free PMC article.
  16. Editorial: The prevalence and outcomes of perianal Crohn’s disease across the treatment eras-Authors’ reply. Gonczi L, Lakatos L, Ilias A, Lakatos PL.Aliment Pharmacol Ther. 2024 Mar;59(5):715-716. doi: 10.1111/apt.17879.PMID: 38349708 No abstract available.
  17. Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials. Wetwittayakhlang P, Bessissow T, Lakatos PL.Expert Opin Emerg Drugs. 2024 Mar;29(1):19-34. doi: 10.1080/14728214.2024.2303116. Epub 2024 Jan 11.PMID: 38193191 Review.
  18. Burden of perianal disease in Crohn’s disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades – Results from a population-based study over four decades. Gonczi L, Lakatos L, Golovics PA, Angyal D, Balogh F, Ilias A, Pandur T, David G, Erdelyi Z, Szita I, Lakatos PL.Aliment Pharmacol Ther. 2024 Mar;59(5):656-665. doi: 10.1111/apt.17836. Epub 2023 Dec 19.PMID: 38115207
  19. Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease. Wetwittayakhlang P, Lakatos PL.J Can Assoc Gastroenterol. 2023 Sep 26;7(1):22-29. doi: 10.1093/jcag/gwad032. eCollection 2024 Feb.PMID: 38314172 Free PMC article.
  20. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Wetwittayakhlang P, Karkout K, Wongcha-Um A, Tselekouni P, Al-Jabri R, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL.Dig Liver Dis. 2024 Jan;56(1):35-42. doi: 10.1016/j.dld.2023.06.022. Epub 2023 Jul 5.PMID: 37419726
  21. Stable Incidence and Risk Factors of Colorectal Cancer in Ulcerative Colitis: A Population-Based Cohort Between 1977-2020. Wetwittayakhlang P, Golovics PA, Gonczi L, Lakatos L, Lakatos PL; VESZPREM EPIDEMIOLOGY STUDY GROUP.Clin Gastroenterol Hepatol. 2024 Jan;22(1):191-193.e3. doi: 10.1016/j.cgh.2023.03.022. Epub 2023 Mar 31.PMID: 37004972 Free article.No abstract available.
  22. Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities. Al-Jabri R, Wetwittayakhlang P, Lakatos PL.J Clin Med. 2023 Nov 27;12(23):7343. doi: 10.3390/jcm12237343.PMID: 38068395
  23. Editorial: Advancing care in Crohn’s disease-Time to standardise bowel preparation scales. Shehab M, Bessissow T.Aliment Pharmacol Ther. 2024 Nov;60(10):1455-1456. doi: 10.1111/apt.18269. Epub 2024 Sep 19.PMID: 39295508 No abstract available.
  24. Management of Colorectal Neoplasia in IBD Patients: Current Practice and Future Perspectives. Derks MEW, Te Groen M, van Lierop LMA, Murthy S, Rubin DT, Bessissow T, Nagtegaal ID, Bemelman WA, Derikx LAAP, Hoentjen F.J Crohns Colitis. 2024 Oct 15;18(10):1726-1735. doi: 10.1093/ecco-jcc/jjae071.PMID: 38741227 Free PMC article.
  25. Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn’s disease. Bessissow T, Narula N, Ma C, In TSH, Pone E, Eberg M, Jairath V; Canadian IBD Research Consortium.Dig Liver Dis. 2024 Oct;56(10):1690-1697. doi: 10.1016/j.dld.2024.04.017. Epub 2024 May 31.PMID: 38821813
  26. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D’Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D’Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group (Bessissow T).JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414.PMID: 39037800 Clinical Trial.
  27. Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Shehab M, Alrashed F, Alsayegh A, Aldallal U, Ma C, Narula N, Jairath V, Singh S, Bessissow T.Clin Gastroenterol Hepatol. 2024 Sep 5:S1542-3565(24)00767-5. doi: 10.1016/j.cgh.2024.07.033. Online ahead of print.PMID: 39182898
  28. Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Shehab M, Hassan A, Alrashed F, Abbas A, Ma C, Narula N, Jairath V, Singh S, Bessissow T.Inflamm Bowel Dis. 2024 Aug 13:izae163. doi: 10.1093/ibd/izae163. Online ahead of print.PMID: 39137239
  29. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group (Bessissow T).N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585.PMID: 39018531 Clinical Trial.
  30. Interim Analysis of a Trial Evaluating the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Inflammatory Bowel Disease. Murthy SK, Bernstein CN, Nguyen GC, Jairath V, Riddell R, Fergusson D; Canadian IBD Research Consortium (Bessissow T).Clin Gastroenterol Hepatol. 2024 Jul;22(7):1535-1538.e2. doi: 10.1016/j.cgh.2023.12.007. Epub 2023 Dec 18.PMID: 38122957
  31. Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn’s Disease: A Systematic Review and Network Meta-Analysis. Vuyyuru SK, Nguyen TM, Murad MH, Narula N, Bessissow T, Zou G, McCurdy JD, Peyrin-Biroulet L, Danese S, Ma C, Singh S, Jairath V.Clin Gastroenterol Hepatol. 2024 Jun;22(6):1190-1199.e15. doi: 10.1016/j.cgh.2023.12.023. Epub 2024 Jan 6.PMID: 38185396 Review.
  32. Resolution of rectal bleeding by day 7 in acute severe ulcerative colitis is prognostic for post-discharge corticosteroid free clinical remission and endoscopic improvement. Narula N, Hamam H, Peerani F, Bessissow T, Bressler B, Dulai PS; Canadian IBD Research Consortium.Am J Gastroenterol. 2024 May 8. doi: 10.14309/ajg.0000000000002860. Online ahead of print.PMID: 38775974
  33. Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study. McCurdy JD, Munir J, Parlow S, Reid J, Yanofsky R, Alenezi T, Meserve J, Becker B, Lahijanian Z, Eddin AH, Mallick R, Ramsay T, Rosenfeld G, Bessissow A, Bessissow T, Jairath V, Singh S, Bruining DH, Macdonald B; Canadian IBD Research Consortium.Clin Gastroenterol Hepatol. 2024 May;22(5):1058-1066.e2. doi: 10.1016/j.cgh.2023.12.006. Epub 2023 Dec 18.PMID: 38122958
  34. Histological Disease Activity as Predictor of Clinical Relapse, Hospitalization, and Surgery in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Shehab M, Al Akram S, Hassan A, Alrashed F, Jairath V, Bessissow T.Inflamm Bowel Dis. 2024 Apr 3;30(4):563-572. doi: 10.1093/ibd/izad119.PMID: 37541185
  35. Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study. Shehab M, Alrashed F, Alyaseen M, Safar Z, Adekunle T, Alfadhli A, Bessissow T.Vaccines (Basel). 2024 Mar 27;12(4):364. doi: 10.3390/vaccines12040364.PMID: 38675746 Free PMC article.
  36. Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn’s disease: A Canadian multi-center study. Bessissow T, Narula N, Ma C, In TSH, Eberg M, Karra K, Jairath V; Canadian IBD Research Consortium.Dig Liver Dis. 2024 Jan;56(1):61-69. doi: 10.1016/j.dld.2023.08.042. Epub 2023 Sep 15.PMID: 37716860
  37. Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease. Papamichael K, Centritto A, Guillo L, Hier J, Sherman Z, Cheifetz AS; International Consortium of Therapeutic Drug Monitoring (Spectrum) (Afif W).Clin Gastroenterol Hepatol. 2024 Oct;22(10):2134-2136.e2. doi: 10.1016/j.cgh.2024.04.005. Epub 2024 Apr 29.PMID: 38692557
  38. Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data. Birck MG, Lukusa L, Choquette D, Boire G, Maksymowych WP, Singh H, Afif W, Bernatsky S.BMC Rheumatol. 2024 Sep 27;8(1):47. doi: 10.1186/s41927-024-00415-5.PMID: 39343928 Free PMC article.
  39. The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study. Seow CH, Marshall JK, Stewart E, Pettengell C, Ward R, Afif W.J Can Assoc Gastroenterol. 2024 Mar 24;7(4):290-298. doi: 10.1093/jcag/gwae010. eCollection 2024 Aug.PMID: 39139218 Free PMC article.
  40. Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies. Jairath V, Afif W, Bressler B, Pope JE, Selchen D, Targownik LE, Panaccione R.J Can Assoc Gastroenterol. 2024 May 15;7(4):282-289. doi: 10.1093/jcag/gwae013. eCollection 2024 Aug.PMID: 39139217 Free PMC article.
  41. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, Zhang H, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Peyrin-Biroulet L, Sands BE, Marano C.Am J Gastroenterol. 2024 May 1;119(5):910-921. doi: 10.14309/ajg.0000000000002621. Epub 2023 Dec 14.PMID: 38095692 Free PMC article.Clinical Trial.
  42. Serious Infections in Offspring Exposed in Utero to Vedolizumab. Gorodensky JH, Bernatsky S, Afif W, St-Pierre Y, Filion KB, Vinet É.Inflamm Bowel Dis. 2024 Mar 1;30(3):496-498. doi: 10.1093/ibd/izad079.PMID: 37172205 Free PMC article.
  43. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn’s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D’Haens GR; GALAXI-1 Study Group (Afif W).Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14.PMID: 38104569
  44. Early Life Exposure to Parental Crohn’s Disease Is Associated With Offspring’s Gut Microbiome, Gut Permeability, and Increased Risk of Future Crohn’s Disease. Lee SH, Bushra M, Qiu L, Griffiths AM, Turpin W, Croitoru K; Crohn’s Colitis Canada Genetic Environmental And Microbial Consortium; Abreu M, Beck P, Bernstein C, Croitoru K, Dieleman L, Feagan B, Griffiths A, Guttman D, Jacobson K, Kaplan G, Krause DO, Madsen K, Marshall J, Moayyedi P, Ropeleski M, Seidman E, Silverberg M, Snapper S, Stadnyk A, Steinhart AH, Surette M, Turner D, Walters T, Vallance B, Aumais G, Bitton A, Cino M, Critch J, Denson L, Deslandres C, El-Matary W, Herfarth H, Higgins P, Huynh HQ, Hyams J, Mack D, McGrath J, Otley A, Panancionne R, Abreu M, Aumais G, Baldassano R, Bernstein C, Cino M, Denson L, Deslandres C, El-Matary W, Griffiths AM, Hedin C, Herfarth H, Higgins P, Hussey S, Huynh HQ, Jacobson K, Keljo D, Kevans D, Lees C, Mack D, Marshall J, McGrath J, Murthy S, Otley A, Panaccione R, Parekh N, Plamondon S, Radford-Smith G, Ropeleski M, Rosh J, Rubin D, Schultz M, Seidman E, Siegel C, Snapper S, Steinhart AH, Turner D.Gastroenterology. 2024 Oct 9:S0016-5085(24)05539-2. doi: 10.1053/j.gastro.2024.09.033. Online ahead of print.PMID: 39384162 Free article.No abstract available.
  45. A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease. Rioux JD, Boucher G, Forest A, Bouchard B, Coderre L, Daneault C, Frayne IR, Legault JT; iGenoMed Consortium; Bitton A, Ananthakrishnan A, Lesage S, Xavier RJ, Des Rosiers C.medRxiv [Preprint]. 2024 Sep 22:2024.09.19.24314034. doi: 10.1101/2024.09.19.24314034.PMID: 39371119 Free PMC article.
  46. Healthy First-Degree Relatives From Multiplex Families vs Simplex Families Have a Higher Subclinical Intestinal Inflammation, a Distinct Fecal Microbial Signature, and Harbor a Higher Risk of Developing Crohn’s Disease. Olivera PA, Martinez-Lozano H, Leibovitzh H, Xue M, Neustaeter A, Espin-Garcia O, Xu W, Madsen KL, Guttman DS, Bernstein CN, Yerushalmi B, Hyams JS, Abreu MT, Marshall JK, Wrobel I, Mack DR, Jacobson K, Bitton A, Aumais G, Panacionne R, Dieleman LA, Silverberg MS, Steinhart AH, Moayyedi P, Turner D, Griffiths AM, Turpin W, Lee SH, Croitoru K; Crohn’s and Colitis Canada (CCC) Genetic, Environmental, Microbial (GEM) Project Research Consortium.Gastroenterology. 2024 Sep 3:S0016-5085(24)05414-3. doi: 10.1053/j.gastro.2024.08.031. Online ahead of print.PMID: 39236898 Free article.
  47. Improving Reliability of Immunological Assays by Defining Minimal Criteria for Cell Fitness. Ivison S, Boucher G, Zheng G, Garcia RV, Kohen R, Bitton A, Rioux JD, Levings MK; iGenoMed Consortium.Immunohorizons. 2024 Sep 1;8(9):622-634. doi: 10.4049/immunohorizons.2300095.PMID: 39248805 Free PMC article.
  48. Environmental Factors Associated With Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada – Genetic, Environmental, Microbial Project. Xue M, Leibovitzh H, Jingcheng S, Neustaeter A, Dong M, Xu W, Espin-Garcia O, Griffiths AM, Steinhart AH, Turner D, Huynh HQ, Dieleman LA, Panaccione R, Aumais G, Bressler B, Bitton A, Murthy S, Marshall JK, Hyams JS, Otley A, Bernstein CN, Moayyedi P, El-Matary W, Fich A, Denson LA, Ropeleski MJ, Abreu MT, Deslandres C, Cino M, Avni-Biron I, Lee SH, Turpin W; CCC GEM Project Research Consortium; Croitoru K.Clin Gastroenterol Hepatol. 2024 Sep;22(9):1889-1897.e12. doi: 10.1016/j.cgh.2024.03.049. Epub 2024 May 16.PMID: 38759825
  49. Development and Validation of an Integrative Risk Score for Future Risk of Crohn’s Disease in Healthy First-Degree Relatives: A Multicentre Prospective Cohort Study. Lee SH, Turpin W, Espin-Garcia O, Xu W, Croitoru K; Crohn’s Colitis Canada-Genetic, Environmental, Microbial Project Research Consortium (Bitton A).Gastroenterology. 2024 Aug 30:S0016-5085(24)05401-5. doi: 10.1053/j.gastro.2024.08.021. Online ahead of print.PMID: 39209122 Free article.No abstract available.
  50. Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis. Coward S, Benchimol EI, Bernstein CN, Avina-Zubieta A, Bitton A, Carroll MW, Cui Y, Hoentjen F, Hracs L, Jacobson K, Jones JL, King J, Kuenzig ME, Lu N, El-Matary W, Murthy SK, Nugent Z, Otley AR, Panaccione R, Peña-Sánchez JN, Singh H, Targownik LE, White D, Windsor JW, Kaplan GG; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC).Am J Gastroenterol. 2024 Aug 1;119(8):1563-1570. doi: 10.14309/ajg.0000000000002687. Epub 2024 Feb 1.PMID: 38299598 Free PMC article.
  51. After Surgically Induced Remission, Ileal and Colonic Mucosa-Associated Microbiota Predicts Crohn’s Disease Recurrence. Hernández-Rocha C, Turpin W, Borowski K, Stempak JM, Sabic K, Gettler K, Tastad C, Chasteau C, Korie U, Hanna M, Khan A, Mengesha E, Bitton A, Schwartz MB, Barrie A, Datta LW, Lazarev M, Brant SR, Rioux JD, McGovern DPB, Duerr RH, Schumm LP, Cho JH, Silverberg MS.Clin Gastroenterol Hepatol. 2024 Jul 4:S1542-3565(24)00592-5. doi: 10.1016/j.cgh.2024.06.022. Online ahead of print.PMID: 38969076
  52. Clinical Predictors of Early and Late Endoscopic Recurrence Following Ileocolonic Resection in Crohn’s Disease. Hernández-Rocha C, Walshe M, Birch S, Sabic K, Korie U, Chasteau C, Miladinova VM, Sabol WB, Mengesha E, Hanna M, Pozdnyakova V, Datta L, Kohen R, Milgrom R, Stempak JM, Bitton A, Brant SR, Rioux JD, McGovern DPB, Duerr RH, Cho JH, Schumm PL, Silverberg MS, Lazarev M.J Crohns Colitis. 2024 Apr 23;18(4):615-627. doi: 10.1093/ecco-jcc/jjad186.PMID: 37976264
  53. Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study. Bernstein CN, Panaccione R, Nugent Z, Marshall DA, Kaplan GG, Vanner S, Dieleman LA, Graff LA, Otley A, Jones J, Buresi M, Murthy S, Borgaonkar M, Bressler B, Bitton A, Croitoru K, Sidani S, Fernandes A, Moayyedi P.Inflamm Bowel Dis. 2024 Mar 27:izae055. doi: 10.1093/ibd/izae055. Online ahead of print.PMID: 38537257
  54. Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study. Kuenzig ME, Bitton A, Carroll MW, Otley AR, Singh H, Kaplan GG, Stukel TA, Mack DR, Jacobson K, Griffiths AM, El-Matary W, Targownik LE, Nguyen GC, Jones JL, Murthy SK, Bernstein CN, Lix LM, Peña-Sánchez JN, Dummer TJB, Spruin S, Fung SG, Nugent Z, Coward S, Cui Y, Coulombe J, Filliter C, Benchimol EI.Inflamm Bowel Dis. 2024 Feb 16:izae010. doi: 10.1093/ibd/izae010. Online ahead of print.PMID: 38366807
  55. Variation in the Care of Children with Inflammatory Bowel Disease Within and Across Canadian Provinces: A Multi-Province Population-Based Cohort Study. Kuenzig ME, Stukel TA, Carroll MW, Kaplan GG, Otley AR, Singh H, Bitton A, Fung SG, Spruin S, Coward S, Cui Y, Nugent Z, Griffiths AM, Mack DR, Jacobson K, Nguyen GC, Targownik LE, El-Matary W, Bernstein CN, Dummer TJB, Jones JL, Lix LM, Murthy SK, Peña-Sánchez JN, Nasiri S, Benchimol EI; Canadian Gastro-Intestinal Epidemiology Consortium.Clin Epidemiol. 2024 Feb 14;16:91-108. doi: 10.2147/CLEP.S449183. eCollection 2024.PMID: 38374886

 

Your donations help deliver specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.

Donate